megace
Phase 2Small molecule
Daewon Pharmaceutical Co., Ltd.megace is one of 9 small molecule programs targeting Atypical Endometrial Hyperplasia. It is currently in Phase 2.
1
Indications
5
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Atypical Endometrial Hyperplasia
#DrugCompanyPhaseTrials
1Prometrium
FerringApproved
Crestor
AstraZenecaPhase 3
Depo-Provera
Eli LillyPhase 3
Megace
Bristol-Myers SquibbPhase 2
Metformin or Insulin Treatment
FFudan University
Phase 3
Mirena
BayerPhase 2
megace
Daewon Pharmaceutical Co., Ltd.Phase 2
Norethisterone Acetate
MMansoura University
Preclinical
Micronized Progesterone
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Phase 12 trials
Clinical Trial1 trial
A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition
Unknown status·—·Phase 1·NCT01383330·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for megace. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details